• Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group

    Source: Buzz FX / 01 Mar 2025 06:51:14   America/Chicago


    Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group Written by MarketBeat March 1, 2025 Share Link copied to clipboard. Research analysts at The Goldman Sachs Group assumed coverage on shares of Summi
    Read more...
Share on,